ONCY

Oncolytics Biotech

ONCY

Market cap $130M

Overview Fund Activity

1.28 USD

-0.03

2.29%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

1.31

+0.03

2.34%

1 day

-2.29%

5 days

12.28%

1 month

48.79%

3 months

121.88%

6 months

103.17%

Year to date

37.66%

1 year

33.51%

5 years

-24.71%

10 years

-79.55%

About: Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Employees: 28

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

140% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 5

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

53% more capital invested

Capital invested by funds: $750K [Q1] → $1.15M (+$399K) [Q2]

10% more funds holding

Funds holding: 50 [Q1] → 55 (+5) [Q2]

0% more ownership

Funds ownership: 1.58% [Q1] → 1.58% (+0%) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$7

447% upside

Avg. target

$7

447% upside

High target

$7

447% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Lake Street

Chad Messer

$7

Buy

Initiated

13 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ONCY published over the past 30 days

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS approximately 2.5x the current standard of care Translational data from multiple studies confirm pelareorep replication in CRC tumors and immune activation Company to define regulatory pathway and advance potential IST in KRAS mutant CRC patient population SAN DIEGO , Sept. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today highlighted clinical and translational data from three metastatic colorectal cancer ("mCRC") studies demonstrating consistent efficacy signals, immune activation, and survival outcomes that exceed historical benchmarks in multiple mCRC treatment settings.

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Data continue to demonstrate a favorable safety profile for pelareorep across multiple indications and in combination with multiple treatments Updated clinical data now account for over 300 gastrointestinal cancer patients, including patients from the GOBLET study, demonstrating pelareorep's potential as a platform therapy Intravenously administered pelareorep continues to show clinical benefit SAN DIEGO , Sept. 2, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today provided an updated safety analysis of pelareorep, which has been administered in over 1,200 patients, including over 300 patients with various gastrointestinal tumors.

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, will participate in two investor conferences next month. CEO Jared Kelly will be meeting with institutional investors at the H.C.

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

SAN DIEGO , Aug. 11, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities SAN DIEGO , Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today reported financial results and recent highlights for the second quarter of 2025. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

SAN DIEGO , Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that the common shares in the capital of the Company (the "Shares") will be voluntarily delisted from the Toronto Stock Exchange ("TSX") at the close of markets on August 22, 2025, pursuant to the Company's application for voluntary delisting and the satisfaction of the conditions to delist from the TSX. The delisting from the TSX will not affect the Company's listing on the Nasdaq.

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

The management team will provide a brief corporate update after the formal portion of the shareholder meeting SAN DIEGO and CALGARY, AB , Aug. 5, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that its upcoming 2025 Annual General Meeting (the "Meeting") will be held virtually at 10:00 a.m. Eastern Time (ET) on Friday, August 8, 2025, as a virtual-only shareholder meeting.

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) support accelerated strategy to drive shareholder value and partnership opportunities SAN DIEGO and CALGARY, AB , July 29, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced it has initiated regulatory discussions with the U.S. Food and Drug Administration (FDA) for a potential registration-enabled pivotal study in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). Assuming discussions with the FDA go as expected, the Company expects to commence study start-up activities before the end of 2025.

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

SAN DIEGO and CALGARY, AB , July 23, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, hosted a key opinion leader (KOL) webinar featuring leading physicians in the fields of oncology and immunotherapy discussing pelareorep's robust clinical data and how it fits in the evolving treatment landscape for pancreatic and gastrointestinal (GI) cancers. The KOLs provided individual presentations and then participated in a roundtable Q&A discussion.

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

SAN DIEGO and CALGARY, AB , July 22, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company specializing in immunotherapy for oncology, received a formal letter (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated July 22, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Company is now in compliance with all Nasdaq listing standards, and its common shares will continue to trade on the Nasdaq Capital Market under the ticker "ONCY.

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

See News Rankings

Charts implemented using Lightweight Charts™